
The Activator I and II solutions provide the substrate for the ELISPOT assay based on silver staining and should be used in conjunction with GABA conjugate (CT351). Prior to use and as final step in the ELISPOT procedure, the solutions should be mixed (1:1) and added to the wells of the ELISPOT plate. The substrate will produce a microscopally black and visually yellow/brown spot. Upon ordering, you will receive one vial containing 9.5 ml Activator I and one vial containing 9.5 ml Activator II for 480 ELISPOT determinations.


References list
- Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination.
- Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
- Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
- Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>

